위식도역류질환 치료제 시장 보고서(2026년)

Gastroesophageal reflux disease (GERD) therapeutics are medications used to treat a chronic condition in which stomach contents move upward into the esophagus, causing symptoms such as heartburn and regurgitation. These therapies work by neutralizing stomach acid or reducing its production to maintain an optimal pH balance in the gastrointestinal tract and prevent the backward flow of acidic contents that lead to reflux.

The main categories of gastroesophageal reflux disease therapeutics include branded and generic products. Branded drugs are medical substances that are supplied only with a prescription from a physician or other authorized prescriber under applicable state or federal regulations, and they are used in the treatment of gastroesophageal reflux disease to relieve symptoms and promote healing of the esophagus. The various drug classes include antacids, proton pump inhibitors, histamine blockers, prokinetic agents, and others, which are distributed through channels such as hospital pharmacies, drug stores, general stores, and supermarkets. These therapeutics are applied in the treatment of Crohn's disease, gastroesophageal reflux disease (GERD), and ulcerative colitis.

Tariffs have influenced the gastroesophageal reflux disease therapeutics market by increasing the cost of imported raw materials and pharmaceutical ingredients, leading to higher production costs for both branded and generic drugs. Hospital pharmacies and retail channels in regions like North America and Europe are most affected due to reliance on imported active pharmaceutical ingredients. Some manufacturers are leveraging tariffs to promote local sourcing and domestic production, which could lead to improved supply chain resilience and potential long-term cost optimization in the market.

The gastroesophageal reflux disease therapeutics market research report is one of a series of new reports from The Business Research Company that provides gastroesophageal reflux disease therapeutics market statistics, including gastroesophageal reflux disease therapeutics industry global market size, regional shares, competitors with a gastroesophageal reflux disease therapeutics market share, detailed gastroesophageal reflux disease therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the gastroesophageal reflux disease therapeutics industry. This gastroesophageal reflux disease therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastroesophageal reflux disease therapeutics market size has grown strongly in recent years. It will grow from $6.08 billion in 2025 to $6.42 billion in 2026 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to rising prevalence of gerd, adoption of proton pump inhibitors, increasing awareness about digestive health, growth of hospital pharmacies, expanding geriatric population.

The gastroesophageal reflux disease therapeutics market size is expected to see strong growth in the next few years. It will grow to $8.38 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to innovation in drug formulations, expansion of e-pharmacies, adoption of telemedicine for gastro care, increasing investment in precision medicine, growing demand for minimally invasive therapies. Major trends in the forecast period include personalized gerd treatment approaches, development of novel drug delivery systems, rising demand for over-the-counter gerd medications, increased focus on gut health and microbiome regulation, integration of remote patient monitoring and telehealth.

The increasing adoption of self-medication is playing a significant role in driving the growth of the gastroesophageal reflux disease (GERD) therapeutics market in the coming years. Self-medication refers to the use of medicines or other remedies to manage health conditions without consulting a healthcare professional. In the context of GERD, self-medication supports symptom management by helping individuals identify and avoid trigger foods, reduce stress, and quit smoking, all of which can substantially alleviate reflux symptoms. For example, in July 2024, according to the Proprietary Association of Great Britain, a UK-based trade association, around 64 million residents in the UK experienced at least one self-treatable condition in 2023. The share of GP-advised cases redirected to over-the-counter self-care increased from 58% in 2023 to 75% in 2024, while consumer confidence in using self-care medications rose to 89%, representing an eight-point increase year over year. As a result, the growing acceptance of self-medication is contributing to the expansion of the gastroesophageal reflux disease therapeutics market.

Major companies operating in the gastroesophageal reflux disease therapeutics market are increasingly focusing on the development of innovative diagnostic solutions such as wireless pH-capsule reflux testing systems. These systems are medical devices used to diagnose and monitor GERD by continuously measuring esophageal acid exposure over an extended period. For instance, in April 2023, Laborie Medical Technologies Corp., a US-based medical testing equipment manufacturer, announced the launch of the alpHaONE system. This wireless pH-capsule reflux testing system is specifically designed for GERD diagnosis and provides up to 96 hours of monitoring with accurate and reliable data. The alpHaONE system features an ergonomic and compact design, large easy-to-press buttons, and a fail-safe capsule delivery mechanism that helps protect the patient's esophagus.

In July 2024, Merit Medical Systems, a US-based provider of disposable medical devices and interventional, diagnostic, and therapeutic systems, acquired EndoGastric Solutions, Inc. for $105 million. Through this acquisition, Merit Medical Systems aims to strengthen its gastrointestinal endoscopy portfolio by adding a minimally invasive, non-pharmacological treatment option for GERD, addressing a substantial unmet clinical need. EndoGastric Solutions is a US-based medical device company known for developing and commercializing the EsophyX Z+ device and related incisionless surgical technologies for GERD treatment.

Major companies operating in the gastroesophageal reflux disease therapeutics market are Pfizer Inc., Johnson and Johnson, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Eisai Co. Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co. Ltd, Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Camber Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., RaQualia Pharma Inc, TWi Pharmaceuticals Inc., Astellas Pharma Inc., SFJ Pharmaceuticals Group, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited

North America was the largest region in the gastroesophageal reflux disease therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroesophageal reflux disease therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the gastroesophageal reflux disease therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gastroesophageal reflux disease (GERD) therapeutics market consists of sales of amino-salicylates (5-ASA), corticosteroids, immunomodulators, antibiotics, biologics, and dopamine receptor antagonist. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gastroesophageal Reflux Disease Therapeutics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses gastroesophageal reflux disease therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gastroesophageal reflux disease therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gastroesophageal reflux disease therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Branded; Generic
• 2) By Drug Class: Antacids; Proton Pump Inhibitors; Histamine Blockers; Pro-Kinetic Agents; Other Drugs Class
• 3) By Distribution Channel: Hospital Pharmacy; Drug Stores; General Stores; Supermarkets
• Subsegments:
• 1) By Branded: Proton Pump Inhibitors (PPIs); H2-Receptor Antagonists; Antacids; Coating Agents
• 2) By Generic: Generic Proton Pump Inhibitors (PPIs); Generic H2-Receptor Antagonists; Generic Antacids; Generic Coating Agents
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson; Novartis AG; Sanofi S.A.; AstraZeneca plc; GlaxoSmithKline plc; Eisai Co. Ltd.; Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries; Dr. Reddy's Laboratories Ltd.; Amneal Pharmaceuticals LLC; CHEPLAPHARM Arzneimittel GmbH; Daewoong Pharmaceutical Co. Ltd; Ironwood Pharmaceuticals Inc.; Sebela Pharmaceuticals Inc.; Camber Pharmaceuticals Inc.; Sun Pharmaceutical Industries Ltd.; RaQualia Pharma Inc; TWi Pharmaceuticals Inc.; Astellas Pharma Inc.; SFJ Pharmaceuticals Group; Boehringer Ingelheim International GmbH; Cadila Pharmaceuticals Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Gastroesophageal Reflux Disease Therapeutics Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Gastroesophageal Reflux Disease Therapeutics Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Gastroesophageal Reflux Disease Therapeutics Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Gastroesophageal Reflux Disease Therapeutics Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Artificial Intelligence & Autonomous Intelligence
  • 4.1.2 Biotechnology, Genomics & Precision Medicine
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.1.5 Industry 4.0 & Intelligent Manufacturing
• 4.2. Major Trends
  • 4.2.1 Personalized Gerd Treatment Approaches
  • 4.2.2 Development Of Novel Drug Delivery Systems
  • 4.2.3 Rising Demand For Over-The-Counter Gerd Medications
  • 4.2.4 Increased Focus On Gut Health And Microbiome Regulation
  • 4.2.5 Integration Of Remote Patient Monitoring And Telehealth

5. Gastroesophageal Reflux Disease Therapeutics Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Clinics
• 5.3 Retail Pharmacies
• 5.4 Online Pharmacies
• 5.5 Geriatric Care Centers

6. Gastroesophageal Reflux Disease Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Gastroesophageal Reflux Disease Therapeutics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Gastroesophageal Reflux Disease Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Gastroesophageal Reflux Disease Therapeutics Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Gastroesophageal Reflux Disease Therapeutics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Gastroesophageal Reflux Disease Therapeutics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Gastroesophageal Reflux Disease Therapeutics Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Gastroesophageal Reflux Disease Therapeutics Market Segmentation

• 9.1. Global Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Branded, Generic
• 9.2. Global Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Antacids, Proton Pump Inhibitors, Histamine Blockers, Pro-Kinetic Agents, Other Drugs Class
• 9.3. Global Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacy, Drug Stores, General Stores, Supermarkets
• 9.4. Global Gastroesophageal Reflux Disease Therapeutics Market, Sub-Segmentation Of Branded, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Proton Pump Inhibitors (PPIs), H2-Receptor Antagonists, Antacids, Coating Agents
• 9.5. Global Gastroesophageal Reflux Disease Therapeutics Market, Sub-Segmentation Of Generic, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Generic Proton Pump Inhibitors (PPIs), Generic H2-Receptor Antagonists, Generic Antacids, Generic Coating Agents

10. Gastroesophageal Reflux Disease Therapeutics Market Regional And Country Analysis

• 10.1. Global Gastroesophageal Reflux Disease Therapeutics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Gastroesophageal Reflux Disease Therapeutics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Gastroesophageal Reflux Disease Therapeutics Market

• 11.1. Asia-Pacific Gastroesophageal Reflux Disease Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Gastroesophageal Reflux Disease Therapeutics Market

• 12.1. China Gastroesophageal Reflux Disease Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Gastroesophageal Reflux Disease Therapeutics Market

• 13.1. India Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Gastroesophageal Reflux Disease Therapeutics Market

• 14.1. Japan Gastroesophageal Reflux Disease Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Gastroesophageal Reflux Disease Therapeutics Market

• 15.1. Australia Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Gastroesophageal Reflux Disease Therapeutics Market

• 16.1. Indonesia Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Gastroesophageal Reflux Disease Therapeutics Market

• 17.1. South Korea Gastroesophageal Reflux Disease Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Gastroesophageal Reflux Disease Therapeutics Market

• 18.1. Taiwan Gastroesophageal Reflux Disease Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Gastroesophageal Reflux Disease Therapeutics Market

• 19.1. South East Asia Gastroesophageal Reflux Disease Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Gastroesophageal Reflux Disease Therapeutics Market

• 20.1. Western Europe Gastroesophageal Reflux Disease Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Gastroesophageal Reflux Disease Therapeutics Market

• 21.1. UK Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Gastroesophageal Reflux Disease Therapeutics Market

• 22.1. Germany Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Gastroesophageal Reflux Disease Therapeutics Market

• 23.1. France Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Gastroesophageal Reflux Disease Therapeutics Market

• 24.1. Italy Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Gastroesophageal Reflux Disease Therapeutics Market

• 25.1. Spain Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Gastroesophageal Reflux Disease Therapeutics Market

• 26.1. Eastern Europe Gastroesophageal Reflux Disease Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Gastroesophageal Reflux Disease Therapeutics Market

• 27.1. Russia Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Gastroesophageal Reflux Disease Therapeutics Market

• 28.1. North America Gastroesophageal Reflux Disease Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Gastroesophageal Reflux Disease Therapeutics Market

• 29.1. USA Gastroesophageal Reflux Disease Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Gastroesophageal Reflux Disease Therapeutics Market

• 30.1. Canada Gastroesophageal Reflux Disease Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Gastroesophageal Reflux Disease Therapeutics Market

• 31.1. South America Gastroesophageal Reflux Disease Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Gastroesophageal Reflux Disease Therapeutics Market

• 32.1. Brazil Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Gastroesophageal Reflux Disease Therapeutics Market

• 33.1. Middle East Gastroesophageal Reflux Disease Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Gastroesophageal Reflux Disease Therapeutics Market

• 34.1. Africa Gastroesophageal Reflux Disease Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Gastroesophageal Reflux Disease Therapeutics Market Regulatory and Investment Landscape

36. Gastroesophageal Reflux Disease Therapeutics Market Competitive Landscape And Company Profiles

• 36.1. Gastroesophageal Reflux Disease Therapeutics Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Gastroesophageal Reflux Disease Therapeutics Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Gastroesophageal Reflux Disease Therapeutics Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

37. Gastroesophageal Reflux Disease Therapeutics Market Other Major And Innovative Companies

• GlaxoSmithKline plc, Eisai Co. Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co. Ltd, Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Camber Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., RaQualia Pharma Inc, TWi Pharmaceuticals Inc., Astellas Pharma Inc.

38. Global Gastroesophageal Reflux Disease Therapeutics Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Gastroesophageal Reflux Disease Therapeutics Market

40. Gastroesophageal Reflux Disease Therapeutics Market High Potential Countries, Segments and Strategies

• 40.1 Gastroesophageal Reflux Disease Therapeutics Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Gastroesophageal Reflux Disease Therapeutics Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Gastroesophageal Reflux Disease Therapeutics Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer